Search
Telisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigationalto be approved for this specific patient population. … [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment
Cenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalIt received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli.
Proparacaine
go.drugbank.com/drugs/DB00807ApprovedVet approvedProparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
International brands: Ak-TaineLumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigational[A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. … [A189093] Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia.
Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigationalAcoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. … [L51958] Similar to the previously developed [tafamidis], acoramidis is used to stabilize TTR in its tetrameric form, preventing the formation of amyloidogenic monomers and the progression of amyloidosis
Thioproperazine
go.drugbank.com/drugs/DB01622ApprovedIt is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. … It is virtually without antiserotonin and hypotensive action and has no antihistaminic property.
Synonyms: N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine-2-sulfonamide, N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine-2-sulfonamideGuanfacine
go.drugbank.com/drugs/DB01018ApprovedInvestigationalGuanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release … [L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274]
Categories: Antihypertensive Agents Indicated for HypertensionProducts: Intuniv XR, Ag-guanfacine XRPrednisolone phosphate
go.drugbank.com/drugs/DB14631ApprovedInvestigationalVet approvedPrednisolone phosphate is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. … [A187463] Prednisolone phosphate was granted FDA Approval on 19 December 1973.[L14144]
Mixtures: OFTALETYC® NFTizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalTizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. … Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons
Mixtures: MYOS -NOR F TABLETASProducts: CIMBRAR(R) SR CAPSULA DE LIBERACIÓN PROGRAMADAClozapine
go.drugbank.com/drugs/DB00363ApprovedInvestigational[A256718] Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL. … Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.